SMAD2 and hepatocellular carcinoma: In hepatocellular carcinoma, farrerol inhibits transforming growth factor-β (TGF-β)-induced migration, invasion, and epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma cells, and suppresses TGF-β-induced phosphorylation of Smad2/3 (Hao et al., 2024).